Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine
J Nucl Med
.
2023 Jun;64(6):986-991.
doi: 10.2967/jnumed.123.265603.
Epub 2023 May 4.
Authors
Jean-Luc Urbain
1
,
Andrew M Scott
2
,
Sze Ting Lee
3
,
John Buscombe
4
,
Charlotte Weston
4
,
Jun Hatazawa
5
,
Seigo Kinuya
6
,
Baljinder Singh
7
,
Mohamad Haidar
8
,
Andrew Ross
9
,
Francois Lamoureux
9
,
Jolanta Kunikowska
10
,
Wolfgang Wadsak
10
,
Rudi Dierckx
10
,
Diana Paez
11
,
Francesco Giammarile
11
,
Kyung-Han Lee
12
,
Joo Hyun O
12
,
Modiselle Moshe
13
,
Lizette Louw
13
,
Stuart More
13
,
Helen Nadel
14
,
Daniel Lee
14
,
Richard Wahl
14
Affiliations
1
Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia; tellmer@snmmi.org.
2
Australian and New Zealand Society of Nuclear Medicine, Vermont South, Victoria, Australia.
3
Australasian Association of Nuclear Medicine Specialists, Balmain, New South Wales, Australia.
4
British Society for Nanomedicine, Liverpool, United Kingdom.
5
Asia Oceania Federation of Nuclear Medicine and Biology, Osaka, Japan.
6
Japanese Society of Nuclear Medicine, Tokyo, Japan.
7
Society of Nuclear Medicine, India, Mumbai, India.
8
Arab Society of Nuclear Medicine, Beirut, Lebanon.
9
Canadian Association of Nuclear Medicine, Rosemère, Quebec, Canada.
10
European Association of Nuclear Medicine, Vienna, Austria.
11
International Atomic Energy Agency, Vienna, Austria.
12
Korean Society of Nuclear Medicine, Seoul, Korea; and.
13
South African Society of Nuclear Medicine, Cape Town, South Africa.
14
Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
PMID:
37142302
DOI:
10.2967/jnumed.123.265603
No abstract available
MeSH terms
Nuclear Medicine*
Precision Medicine
Radionuclide Imaging
Radiopharmaceuticals* / therapeutic use
Theranostic Nanomedicine
Substances
Radiopharmaceuticals